scispace - formally typeset
Search or ask a question
Institution

University of Colorado Denver

EducationDenver, Colorado, United States
About: University of Colorado Denver is a education organization based out in Denver, Colorado, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 27444 authors who have published 57213 publications receiving 2539937 citations. The organization is also known as: CU Denver & UCD.


Papers
More filters
Journal ArticleDOI
TL;DR: This review deals with emerging evidence of an association between systemic or local hypoxia and inflammation in a variety of diseases and points to new ways of treating inflammatory disorders or conditions such as certain cancers with intralesional Hypoxia.
Abstract: This review deals with emerging evidence of an association between systemic or local hypoxia and inflammation in a variety of diseases. The evidence points to new ways of treating inflammatory disorders or conditions such as certain cancers with intralesional hypoxia.

1,603 citations

Journal ArticleDOI
TL;DR: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC and independent of EGFR assessment method, EGFR+/P-Akt+ patients had a statistically significantly better outcome than EGFR-, P- akt-, or EGFR-/Akt- patients.
Abstract: Background: Gefitinib is a selective inhibitor of the epidermal growth factor (EGFR) tyrosine kinase, which is overexpressed in many cancers, including non-small-cell lung cancer (NSCLC). We carried out a clinical study to compare the relationship between EGFR gene copy number, EGFR protein expression, EGFR mutations, and Akt activation status as predictive markers for gefitinib therapy in advanced NSCLC. Methods: Tumors from 102 NSCLC patients treated daily with 250 mg of gefitinib were evaluated for EGFR status by fluorescence in situ hybridization (FISH), DNA sequencing, and immunohistochemistry and for Akt activation status (phospho-Akt [P-Akt]) by immunohistochemistry. Time to progression, overall survival, and 95% confidence intervals (CIs) were calculated and evaluated by the Kaplan-Meier method; groups were compared using the log-rank test. Risk factors associated with survival were evaluated using Cox proportional hazards regression modeling and multivariable analysis. All statistical tests were two-sided. Results: Amplification or high polysomy of the EGFR gene (seen in 33 of 102 patients) and high protein expression (seen in 58 of 98 patients) were statistically significantly associated with better response (36% versus 3%, mean difference = 34%, 95% CI = 16.6 to 50.3; P<.001), disease control rate (67% versus 26%, mean difference = 40.6%, 95% CI = 21.5 to 59.7; P<.001), time to progression (9.0 versus 2.5 months, mean difference = 6.5 months, 95% CI = 2.8 to 10.3; P<.001), and survival (18.7 versus 7.0 months, mean difference = 11.7 months, 95% CI = 2.1 to 21.4; P =.03). EGFR mutations (seen in 15 of 89 patients) were also statistically significantly related to response and time to progression, but the association with survival was not statistically significant, and 40% of the patients with mutation had progressive disease. In multivariable analysis, only high EGFR gene copy number remained statistically significantly associated with better survival (hazard ratio = 0.44, 95% CI = 0.23 to 0.82). Independent of EGFR assessment method, EGFR + /P-Akt + patients had a statistically significantly better outcome than EGFR - , P-Akt - , or EGFR + /P-Akt - patients. Conclusions: High EGFR gene copy number identified by FISH may be an effective molecular predictor for gefitinib efficacy in advanced NSCLC.

1,595 citations

Journal ArticleDOI
TL;DR: A cross-cultural study of behavior in ultimatum, public goods, and dictator games in a range of small-scale societies exhibiting a wide variety of economic and cultural conditions found the canonical model – based on self-interest – fails in all of the societies studied.
Abstract: Researchers from across the social sciences have found consistent deviations from the predictions of the canonical model of self-interest in hundreds of experiments from around the world. This research, however, cannot determine whether the uniformity re- sults from universal patterns of human behavior or from the limited cultural variation available among the university students used in virtually all prior experimental work. To address this, we undertook a cross-cultural study of behavior in ultimatum, public goods, and dictator games in a range of small-scale societies exhibiting a wide variety of economic and cultural conditions. We found, first, that the canonical model - based on self-interest - fails in all of the societies studied. Second, our data reveal substantially more behavioral vari- ability across social groups than has been found in previous research. Third, group-level differences in economic organization and the structure of social interactions explain a substantial portion of the behavioral variation across societies: the higher the degree of market integration and the higher the payoffs to cooperation in everyday life, the greater the level of prosociality expressed in experimental games. Fourth, the available individual-level economic and demographic variables do not consistently explain game behavior, either within or across groups. Fifth, in many cases experimental play appears to reflect the common interactional patterns of everyday life.

1,589 citations

Journal ArticleDOI
TL;DR: The task group report includes a review of the literature to identify reported clinical findings and expected outcomes for this treatment modality.
Abstract: Task Group 101 of the AAPM has prepared this report for medical physicists, clinicians, and therapists in order to outline the best practice guidelines for the external-beam radiation therapy technique referred to as stereotactic body radiation therapy (SBRT). The task group report includes a review of the literature to identify reported clinical findings and expected outcomes for this treatment modality. Information is provided for establishing a SBRT program, including protocols, equipment, resources, and QA procedures. Additionally, suggestions for developing consistent documentation for prescribing, reporting, and recording SBRT treatment delivery is provided.

1,586 citations

Journal ArticleDOI
Dominik Sturm1, Hendrik Witt2, Hendrik Witt1, Volker Hovestadt1, Dong Anh Khuong-Quang3, David T.W. Jones1, Carolin Konermann1, Elke Pfaff1, Martje Tönjes1, Martin Sill1, Sebastian Bender1, Marcel Kool1, Marc Zapatka1, Natalia Becker1, Manuela Zucknick1, Thomas Hielscher1, Xiaoyang Liu3, Adam M. Fontebasso4, Marina Ryzhova, Steffen Albrecht4, Karine Jacob3, Marietta Wolter5, Martin Ebinger6, Martin U. Schuhmann6, Timothy E. Van Meter7, Michael C. Frühwald8, Holger Hauch, Arnulf Pekrun, Bernhard Radlwimmer1, Tim Niehues9, Gregor Von Komorowski, Matthias Dürken, Andreas E. Kulozik2, Jenny Madden10, Andrew M. Donson10, Nicholas K. Foreman10, Rachid Drissi11, Maryam Fouladi11, Wolfram Scheurlen9, Andreas von Deimling2, Andreas von Deimling1, Camelia M. Monoranu12, Wolfgang Roggendorf12, Christel Herold-Mende2, Andreas Unterberg2, Christof M. Kramm13, Jörg Felsberg5, Christian Hartmann14, Benedikt Wiestler2, Wolfgang Wick2, Till Milde2, Till Milde1, Olaf Witt2, Olaf Witt1, Anders Lindroth1, Jeremy Schwartzentruber3, Damien Faury3, Adam Fleming3, Magdalena Zakrzewska15, Pawel P. Liberski15, Krzysztof Zakrzewski16, Peter Hauser17, Miklós Garami17, Almos Klekner18, László Bognár18, Sorana Morrissy19, Florence M.G. Cavalli19, Michael D. Taylor19, Peter van Sluis20, Jan Koster20, Rogier Versteeg20, Richard Volckmann20, Tom Mikkelsen21, Kenneth Aldape22, Guido Reifenberger5, V. Peter Collins23, Jacek Majewski3, Andrey Korshunov1, Peter Lichter1, Christoph Plass1, Nada Jabado3, Stefan M. Pfister2, Stefan M. Pfister1 
TL;DR: It is demonstrated that each H3F3A mutation defines an epigenetic subgroup of GBM with a distinct global methylation pattern, and that they are mutually exclusive with IDH1 mutations, which characterize a third mutation-defined subgroup.

1,557 citations


Authors

Showing all 27683 results

NameH-indexPapersCitations
Matthew Meyerson194553243726
Charles A. Dinarello1901058139668
Gad Getz189520247560
Gordon B. Mills1871273186451
Jasvinder A. Singh1762382223370
David Haussler172488224960
Donald G. Truhlar1651518157965
Charles M. Perou156573202951
David Cella1561258106402
Bruce D. Walker15577986020
Marco A. Marra153620184684
Thomas E. Starzl150162591704
Marc Humbert1491184100577
Rajesh Kumar1494439140830
Martin J. Blaser147820104104
Network Information
Related Institutions (5)
University of Pittsburgh
201K papers, 9.6M citations

98% related

University of California, San Francisco
186.2K papers, 12M citations

97% related

University of North Carolina at Chapel Hill
185.3K papers, 9.9M citations

97% related

Duke University
200.3K papers, 10.7M citations

97% related

University of Pennsylvania
257.6K papers, 14.1M citations

96% related

Performance
Metrics
No. of papers from the Institution in previous years
YearPapers
20241
202383
2022358
20213,830
20203,913
20193,632